Adverum Biotechnologies Inc (ADVM)
7.525
+0.12
(+1.55%)
USD |
NASDAQ |
Nov 04, 16:00
7.53
0.00 (0.00%)
Pre-Market: 20:00
Adverum Biotechnologies Cash from Financing (Quarterly): -0.116M for June 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -0.116M |
| March 31, 2024 | 119.88M |
| December 31, 2023 | 0.166M |
| September 30, 2023 | -0.105M |
| June 30, 2023 | 0.008M |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.242M |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.362M |
| March 31, 2022 | 0.003M |
| December 31, 2021 | 0.375M |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.517M |
| March 31, 2021 | 1.505M |
| December 31, 2020 | 0.376M |
| September 30, 2020 | 204.25M |
| June 30, 2020 | 2.731M |
| March 31, 2020 | 148.62M |
| December 31, 2019 | 26.77M |
| September 30, 2019 | -0.091M |
| June 30, 2019 | 1.881M |
| March 31, 2019 | -0.37M |
| December 31, 2018 | -0.021M |
| Date | Value |
|---|---|
| September 30, 2018 | -0.015M |
| June 30, 2018 | 0.187M |
| March 31, 2018 | 69.80M |
| December 31, 2017 | 16.64M |
| September 30, 2017 | -0.239M |
| June 30, 2017 | 0.155M |
| March 31, 2017 | 0.187M |
| December 31, 2016 | 0.203M |
| September 30, 2016 | 0.004M |
| June 30, 2016 | 0.087M |
| March 31, 2016 | 0.262M |
| December 31, 2015 | -0.275M |
| September 30, 2015 | 0.05M |
| June 30, 2015 | 0.11M |
| March 31, 2015 | 138.98M |
| December 31, 2014 | -0.505M |
| September 30, 2014 | 117.99M |
| June 30, 2014 | 46.96M |
| March 31, 2014 | 1.00M |
| December 31, 2013 | 0.98M |
| September 30, 2013 | 0.70M |
| June 30, 2013 | 0.50M |
| March 31, 2013 | 0.30M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.116M
Minimum
Jun 2024
204.25M
Maximum
Sep 2020
26.61M
Average
0.362M
Median
Jun 2022
Cash from Financing (Quarterly) Benchmarks
| EyePoint Pharmaceuticals Inc | 0.329M |
| Cassava Sciences Inc | 101.39M |
| Regenxbio Inc | -9.445M |
| Editas Medicine Inc | 0.322M |
| Apellis Pharmaceuticals Inc | 42.49M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -19.84M |
| Cash from Investing (Quarterly) | -2.327M |
| Free Cash Flow | -89.12M |
| Free Cash Flow Per Share (Quarterly) | -0.9524 |
| Free Cash Flow Yield | -82.31% |